-
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
-
A Phase 1/2 Study Of STP938 For Adult Subjects With Relapsed/Refractory B-Cell And T-Cell Lymphomas
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
-
Trial Using Keytruda As Initial Therapy In The Treatment Of Advanced Mycosis Fungoides
Jacksonville, FL
The purpose of this trial is to evaluate the antitumor activity of Pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy.
-
Cutaneous Lymphoma Biobank Study
Scottsdale/Phoenix, AZ
The purpose of this study is to create a cutaneous lymphoma tissue repository. This is a highly significant first step in collecting specimens for future analysis to understand the underlying drivers of disease.
-
Cutaneous Lymphoma Database
Scottsdale/Phoenix, AZ
The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.
-
Extracorporeal Photopheresis And Mogamulizumab For The Treatment Of Erythrodermic Cutaneous T Cell Lymphoma
Scottsdale/Phoenix, AZ
The purpose of this study is to determine the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma.
-
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, And Quality Of Life In Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Scottsdale/Phoenix, AZ
The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 1 year from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.
-
Building A Healthy Body After Cancer: Challenges And Opportunities In Healthy Exercise After Treatment For Young Adult Lymphoma Survivors
Rochester, MN
Exercise can benefit young adult cancer survivors by improving cardiovascular and pulmonary function, reducing fatigue, improving quality of life, and may even increase long term survival. Our goal is to identify specific barriers to exercise faced by young adult lymphoma survivors. In addition, we will look to survivors to guide us on the particular ways in which a health care institution might support them in physical activity. Our specific aims are: evaluate young adult lymphoma survivors’ knowledge regarding benefits of exercise after cancer treatment, identify barriers to exercise experienced by young adult lymphoma survivors, and understand the types of exercise ...
-
A Study To Evaluate Feasibility Of In Vivo Sensitivity Screen Using Direct Tumor Microinjection And FDG-PET In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Or Stage IV Breast Cancer
Rochester, MN
The purpose of this study is to assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions).